Global Endoscope Reprocessing Device Market Booming with the Major Players Like Medivators, Olympus, STERIS, Getinge, Hoya and Laboratoires Anios

Researchmoz added Most up-to-date research on "Global Endoscope Reprocessing Device Market Booming with the Major Players Like Medivators, Olympus, STERIS, Getinge, Hoya and Laboratoires Anios" to its huge collection of research reports.

An endoscopy (looking inside) is used medicine look inside the body.[1]The endoscopy procedure uses endoscope examine the interior of a hollow organ or cavity of the body. Unlike many other medical imaging techniques,endoscopes are inserted directly into the organ.

With 8.2% CAGR, the hospital segment of the end user type dominates the global endoscope reprocessing device market.

The global Endoscope Reprocessing Device market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Endoscope Reprocessing Device market based on company, product type, end user and key regions.

This report studies the global market size of Endoscope Reprocessing Device in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Endoscope Reprocessing Device in these regions.

This research report categorizes the global Endoscope Reprocessing Device market by top players/brands, region, type and end user. This report also studies the global Endoscope Reprocessing Device market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2039575

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Medivators
Olympus
STERIS
Getinge
Hoya
Laboratoires Anios
Custom Ultrasonics
SciCan
Shinva
ARC
Antonio Matachana

Market size by Product
Automated Endoscope Reprocessor
Washer Disinfector
Sterilizer
Ultrasonic Washer
Drying and Storage Cabinet
Market size by End User
Hospitals
Ambulatory Surgical Center
Specialty Clinics

Browse TOC @ https://www.researchmoz.us/global-endoscope-reprocessing-device-market-insights-forecast-to-2025-report.html/toc

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Endoscope Reprocessing Device market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Endoscope Reprocessing Device market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Endoscope Reprocessing Device companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Endoscope Reprocessing Device submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Endoscope Reprocessing Device are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Endoscope Reprocessing Device market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Hips & Knees Reconstructive Market Forecast By Top Leading Manufacturers | Zimmer, DePuy, Smith & Nephew, Stryker and MicroPort

Researchmoz added Most up-to-date research on "Global Hips & Knees Reconstructive Market Forecast By Top Leading Manufacturers | Zimmer, DePuy, Smith & Nephew, Stryker and MicroPort" to its huge collection of research reports.

Global Hips & Knees Reconstructive Market

Hip implants are medical devices intended to restore and relieve mobility and relieve pain usually associated with arthritis and hip diseases or injuries. Currently there are five types of total hip replacement available with different bearing surfaces. Metal-on-Polyethylene The ball is made of metal and the socket is made of polyethylene or has a plastic lining. Metal-on-Metal The ball and socket are made of metal. Ceramic-on-Polyethylene The ball is made of ceramic and the socket is made of plastic or has a plastic lining. Ceramic-on-Ceramic The ball is made of ceramic and the socket has a ceramic lining. Ceramic-on-Metal The ball is made of ceramic and the socket has a ceramic lining.

In terms of revenue share, the cementless fixation segment dominated the global hips & knees reconstructive market in 2017 and is expected to continue its dominance throughout the forecast period, registering a CAGR of 6.4% in terms of value.

The global Hips & Knees Reconstructive market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hips & Knees Reconstructive market based on company, product type, end user and key regions.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2039603

This report studies the global market size of Hips & Knees Reconstructive in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hips & Knees Reconstructive in these regions.

This research report categorizes the global Hips & Knees Reconstructive market by top players/brands, region, type and end user. This report also studies the global Hips & Knees Reconstructive market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Zimmer
DePuy
Smith & Nephew
Stryker
MicroPort
B. Braun Melsungen
Exactech
Limacorporate

Browse TOC @ https://www.researchmoz.us/global-hips-and-knees-reconstructive-market-insights-forecast-to-2025-report.html/toc

Market size by Product
Hip Reconstruction
Knee Reconstruction

Market size by End User
Hospitals
Orthopaedic Clinics
Ambulatory Surgical Centres

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Hips & Knees Reconstructive market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hips & Knees Reconstructive market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hips & Knees Reconstructive companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hips & Knees Reconstructive submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hips & Knees Reconstructive are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hips & Knees Reconstructive market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Platinum Mining Market Analysis of Top Impacting Factors with Key Players - Anglo American Platinum Ltd, Lonmin Plc, MMC Norilsk Nickel and Sibanye-Stillwater

Researchmoz added Most up-to-date research on "Global Platinum Mining Market Analysis of Top Impacting Factors with Key Players - Anglo American Platinum Ltd, Lonmin Plc, MMC Norilsk Nickel and Sibanye-Stillwater" to its huge collection of research reports.

GlobalData's "Global Platinum Mining to 2022" provides a comprehensive coverage on global platinum industry. It provides historical and forecast data on platinum production by country, platinum reserves, consumption to 2022. The report also includes a demand drivers section providing information on factors that are affecting the global platinum industry. It further provides mines and projects count by company by status, and by region, profiles of major platinum producers, information on the major active, planned and exploration projects by region.

Scope
- The report contains an overview of global platinum mining industry inlcuding key demand driving factors affecting the global platinum mining industry.
- It provides detailed information on reserves, reserves by country, production, production by country, major operating mines, competitive landscape, major exploration and development projects, consumption, and consumption by country.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2027970

Reasons to buy
- To gain an understanding of the global platinum mining industry, relevant driving factors
- To understand historical and forecast trend on global platinum production, and consumption
- To identify key players in the global platinum mining industry
- To gain an understanding of major active, exploration and development projects.

Browse TOC @ https://www.researchmoz.us/global-platinum-mining-to-2022-report.html/toc

Table Of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Global Platinum Mining to 2022 5
2.1 Key Highlights 5
3 Global Platinum Mining: Reserves, Production, Consumption and Trade 6
3.1 Reserves by Country 6
3.2 Historical and Forecast Production 7
3.2.1 Production by country 10
3.2.2 South Africa 11
3.2.3 Russia 13
3.2.4 Zimbabwe 15
3.2.5 Canada 17
3.3 Active Mines 20
3.4 Exploration Projects 23
3.5 Development Projects 27
3.6 Global Platinum Consumption and Trade 30
3.6.1 China 32
3.6.2 Japan 34
3.7 Factors Affecting the Demand for Platinum 36
3.7.1 Demand from Chinas jewelry and automotive sector 38

United States Healthcare IT Market Set for Rapid Growth During by 2025 - GE Healthcare LLC, Cerner Corp and Philips Healthcare

Researchmoz added Most up-to-date research on "United States Healthcare IT Market Set for Rapid Growth During by 2025 - GE Healthcare LLC, Cerner Corp and Philips Healthcare" to its huge collection of research reports.

GlobalDatas new report, United States Healthcare IT Market Outlook to 2025, provides key market data on the United States Healthcare IT market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market categories - Blood Pressure Monitors, Clinical IT Systems, Fetal Monitors, Medical Imaging Information Systems, Micro-Electromechanical Sensors, Multiparameter Patient Monitoring, Neonatal Monitors, Patient Monitoring Accessories and Remote Patient Monitoring.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2027988


Scope
- Market size and company share data for Healthcare IT market categories - Blood Pressure Monitors, Clinical IT Systems, Fetal Monitors, Medical Imaging Information Systems, Micro-Electromechanical Sensors, Multiparameter Patient Monitoring, Neonatal Monitors, Patient Monitoring Accessories and Remote Patient Monitoring.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2015 to 2025.
- 2017 company share and distribution share data for Healthcare IT market.
- Global corporate-level profiles of key companies operating within the United States Healthcare IT market.
- Key players covered include GE Healthcare LLC, Cerner Corp, Philips Healthcare, and Others.


Browse TOC @ https://www.researchmoz.us/united-states-healthcare-it-market-outlook-to-2025-blood-pressure-monitors-clinical-it-systems-fetal-monitors-neonatal-monitors-and-others-report.html/toc


Reasons to buy
- Develop business strategies by identifying the key market categories poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution - Identify, understand and capitalize.

Global Cancer Immunotherapies Market To See Worldwide Massive Growth By Top Companies – Celgene, Merck & Co., Bristol-Myers Squibb and Roche

Researchmoz added Most up-to-date research on "Global Cancer Immunotherapies Market To See Worldwide Massive Growth By Top Companies – Celgene, Merck & Co., Bristol-Myers Squibb and Roche" to its huge collection of research reports.

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patients immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877886

Scope

- Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?

- The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?

- There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?

- The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?

- There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?

- Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?

Browse TOC @ https://www.researchmoz.us/global-cancer-immunotherapies-market-to-2024-increased-uptake-of-immune-checkpoint-inhibitors-driving-growth-supported-by-a-large-robust-pipeline-report.html/toc

Reasons to buy

- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drugs mechanism of action.

- Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.

- Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.

- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals

Respiratory Tract Infections Drug Development Pipeline Review, 2018 - Key Players Such As Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline

Researchmoz added Most up-to-date research on "Respiratory Tract Infections Drug Development Pipeline Review, 2018 - Key Players Such As Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline" to its huge collection of research reports.

Respiratory Tract Infections Drug Development

This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877889

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/respiratory-tract-infections-drug-development-pipeline-review-2018-report.html/toc

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Asia-Pacific Colorectal Cancer Therapeutics Market - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market, 2024

Researchmoz added Most up-to-date research on "Asia-Pacific Colorectal Cancer Therapeutics Market - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market, 2024" to its huge collection of research reports.

Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1880947

In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients.

A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Scope

• The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
• How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
• What effect will patent expirations of currently branded therapies have on market value?
• The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
• What implications will the increased focus on targeted therapies have on the future of CRC treatment?
• Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
• The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
• How could changes in risk factors such as population age, obesity and lifestyle influence the market?
• Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
• How do deal frequency and value compare between target families and
• molecule types?
• What were the terms and conditions of key licensing deals?

Browse TOC @ https://www.researchmoz.us/colorectal-cancer-therapeutics-in-asiapacific-markets-to-2024-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.